EAT is up +49.38%% since April’24 pick View All Top Buy Picks
RSI low/high Values: [ 25 - 80 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of MGCLF
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

FAQ

What is the symbol for MGC Pharmaceuticals Limited Stock and on which exchange is it traded?
The symbol for MGC Pharmaceuticals Limited is MGCLF and it is traded on the PINK (Pink Sheets).

Should I buy or sell MGC Pharmaceuticals Limited Stock?
MGC Pharmaceuticals Limited holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy MGC Pharmaceuticals Limited Stock?
MGC Pharmaceuticals Limited Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy MGC Pharmaceuticals Limited Stock.

What's the current price of MGC Pharmaceuticals Limited Stock?
As of the end of day on the Jun 25, 2024, the price of an MGC Pharmaceuticals Limited (MGCLF) share was $0.268.

What is the 52-week high and low for MGC Pharmaceuticals Limited Stock?
The 52-week high for MGC Pharmaceuticals Limited Stock is $0.425 and the 52-week low is $0.0006.

What is the market capitalization of MGC Pharmaceuticals Limited Stock?
As of the Jun 25, 2024, the market capitalization of MGC Pharmaceuticals Limited is 12.112M.

When is the next earnings date for MGC Pharmaceuticals Limited?
The upcoming earnings date for MGC Pharmaceuticals Limited is Jul 26, 2024.
Click to get the best stock tips daily for free!

About MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Roy... MGCLF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT